Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,188 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER2-normal Clear all

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions: MRI; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 55
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more

Conditions: Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
Interventions: Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Clearwater, Florida • Tampa, Florida

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Interventions: Palbociclib, Bosutinib, Fulvestrant; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer, Gastric/Gastroesophageal Junction Cancer
Interventions: KN026; Drug
Lead sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Interventions: ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Altanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: Lapatinib; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
Interventions: Elacestrant, Trastuzumab Deruxtecan; Drug
Lead sponsor: Kristina A. Fanucci; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Interventions: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab, AMG 386 30 mg/kg, Capecitabine and Lapatinib, AMG 386 10 mgkg, Paclitaxel and Trastuzumab, AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 13
States / cities: Tucson, Arizona • Boca Raton, Florida • Iowa City, Iowa + 9 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,926 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Trastuzumab, Oxaliplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 7
States / cities: Bowling Green, Kentucky • Alexandria, Louisiana • Baton Rouge, Louisiana + 4 more

Conditions: HER2-positive Breast Cancer
Interventions: HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HER2-positive Breast Cancer, Breast Cancer
Interventions: HER2-targeted therapy, Tamoxifen, No Radiation Therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
Interventions: Talazoparib, ASTX727; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana • Winston-Salem, North Carolina

Conditions: Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
Interventions: ONC201; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer Metastatic
Interventions: Paclitaxel, Pelareorep, Avelumab; Drug · Biological
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more

Conditions: Breast Cancer
Interventions: Rapamycin, Trastuzumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Conditions: Advanced Solid Tumors, HER2 Mutation
Interventions: BAY2927088; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more

Search by objective public record fields.

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Study of Screening Brain MRIs in Stage IV Breast Cancer

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

A Study of Skipping Radiation Therapy in People With Breast Cancer

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)